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Laboratory recommendations for scoring deep molecular
responses following treatment for chronic myeloid leukemia
NCP Cross1,2, HE White1,2, D Colomer3, H Ehrencrona4, L Foroni5, E Gottardi6, T Lange7, T Lion8, K Machova Polakova9, S Dulucq10,
G Martinelli11, E Oppliger Leibundgut12, N Pallisgaard13, G Barbany14, T Sacha15, R Talmaci16, B Izzo17, G Saglio6, F Pane17,18,
MC Müller19 and A Hochhaus20
Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve
very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is
withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate deﬁnition of deep molecular
responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We
previously published proposals for broad standardized deﬁnitions of MR at different levels of sensitivity. Here we present detailed
laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing
laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
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INTRODUCTION
Molecular monitoring provides important prognostic information
for individual chronic myeloid leukemia (CML) patients under-
going therapy, and international treatment recommendations
incorporate speciﬁc time-dependent molecular milestones to help
determine whether a patient is responding optimally or not.1,2
Molecular measurements are made by reverse transcriptase
quantitative PCR (RT-qPCR) to estimate the amount of BCR-ABL1
mRNA relative to an internal reference gene, most commonly
ABL1, GUSB or BCR.3,4 The results are expressed on an International
Scale (IS) as a percentage, with 100% BCR-ABLIS corresponding to
the International Randomized Study of Interferon and STI571 (IRIS)
study standardized baseline and 0.1% BCR-ABLIS being deﬁned
as a major molecular response (MMR or MR3; 3 log reduction
from the standardized baseline).3 Expression of results on the IS
depends on each testing laboratory either having obtained a
laboratory-speciﬁc conversion factor (CF) by sample exchange
with an established reference laboratory or by using kits and
reagents that have been calibrated to the World Health
Organization International Genetic Reference Panel for quantita-
tion of BCR-ABL1 mRNA.4–9
Efforts to standardize molecular monitoring to the IS focused
initially on detectable residual disease and in particular whether a
patient had or had not achieved particular milestones, for
example, 10% BCR-ABLIS or 0.1% BCR-ABLIS at various time points.
However, with longer follow-up, it became apparent that many
patients treated with imatinib achieved deeper levels of response,
with BCR-ABL1 becoming undetectable in a minority of cases.10
This, along with the fact that second-generation tyrosine kinase
inhibitors produce faster and deeper responses, compared with
imatinib,11,12 prompted the need for robust, standardized deﬁni-
tions of deep MR. Such deﬁnitions are particularly important in the
context of studies that are enrolling patients with sustained deep
responses into treatment-free protocols.13,14
We previously published proposals for broad standardized
deﬁnitions of MR at different levels of sensitivity (MR4, MR4.5, and
so on; collectively referred to as ‘deep MR’), which were endorsed
by the European LeukemiaNet in their most recent recommenda-
tions for the treatment of CML patients.1,15 These broad
deﬁnitions, however, and clinical studies that have been published
to date do not provide the technical details and interpretation
to enable laboratories to categorize patients in a standardized
manner. As part of the European Treatment and Outcome Study
(EUTOS), we have developed laboratory proposals, as detailed
below, to enable testing laboratories to deﬁne MR in a
reproducible manner. These proposals were developed by
consensus over several meetings and are described in detail in
this paper, along with several examples. The terminology
employed is based on the recommendations of the Minimum
Information for Publication of Quantitative Real-Time PCR Experi-
ments (MIQE) guidelines16 and the proposal focuses on qPCR
assays for the most common BCR-ABL1 variants (e13a2 and/or
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e14a2; 97% of CML patients) that use an external plasmid
calibrator to estimate numbers of target molecules.
REFERENCE GENES OTHER THAN ABL1
The published deﬁnitions of MR focus on the use of ABL1 as a
reference gene as this is used by the majority of laboratories
worldwide.15 Of the principal alternative reference genes,3 GUSB is
used by a signiﬁcant minority of European laboratories, whereas
BCR is used primarily in Australasia and some US laboratories.
We have focused here on extending the MR deﬁnitions when
BCR-ABL1 is undetectable to include GUSB; further work will be
required to extend these deﬁnitions to include BCR.
To determine the correspondence between ABL1 and GUSB, we
collected data from three centers that routinely analyzed the
expression of both genes in parallel. We focused on CML samples
that were o10% BCR-ABLIS and had 410 000 ABL1 copies. Of
1567 samples, the median ratio of GUSB/ABL1 was 2.4 in the same
volume of cDNA and therefore we consider that, for the purpose
of deﬁning deep MR, 10 000 ABL1 transcripts are equivalent
to 24 000 GUSB transcripts. The previously published15 deﬁnitions
of MR can therefore be expanded as follows:
● MR4 (⩾4-log reduction from IRIS baseline) = either (i) detectable
disease ⩽ 0.01% BCR-ABLIS or (ii) undetectable disease in cDNA
with 10 000–31 999 ABL1 transcripts or 24 000–76 999 GUSB
transcripts.
● MR4.5 (⩾4.5-log reduction from IRIS baseline) = either (i)
detectable disease ⩽ 0.0032% BCR-ABLIS or (ii) undetectable
disease in cDNA with 32 000–99 999 ABL1 transcripts or 77 000–
239 999 GUSB transcripts.
● MR5 (⩾5-log reduction from IRIS baseline) = either (i) detectable
disease ⩽ 0.001% BCR-ABLIS or (ii) undetectable disease in cDNA
with ⩾ 100 000 ABL1 transcripts ⩾ 240 000 GUSB transcripts.
Although GUSB laboratories may use these deﬁnitions,
we suggest that they should ideally derive their own correspon-
dence between ABL1 and GUSB (or other reference gene) using at
least 50–100 remission (o10% BCR-ABLIS) samples to derive their
own cutoffs for different MR levels. Before making this compar-
ison, the ampliﬁcation conditions should be optimized and in
particular the ampliﬁcation efﬁciency for the two genes should be
the same. This can be achieved easily for ABL1, GUSB and BCR (and
BCR-ABL1) using the ERM-AD623 plasmid.17 For laboratory-
developed tests, we further recommend that ERM-AD623 is used
directly as a qPCR calibrator for routine analysis or indirectly as a
calibrator for in-house plasmid dilutions.
DEFINING DETECTABLE AND UNDETECTABLE DISEASE
There are several ways in which testing laboratories differ in how
they deﬁne disease as detectable or undetectable. For individual
ampliﬁcation reactions and runs, we recommend that the
established Europe Against Cancer criteria are used.18 In particular:
● The cutoff for positivity should correspond to a quantiﬁcation
cycle (Cq) of intercept +1 (which should generally lead to
cutoffs of 41–42 Cq). In other words, samples with a Cq higher
than intercept +1 should be considered as undetectable.
● The ‘no-template control’ wells and reagent blanks should
ideally not cross the threshold at any point but should certainly
be at least 2 Cq above the intercept Cq for that run. If this is not
the case, then the run must be considered as failed.
A major variable between centers is the number of replicate
assays that are performed for each sample and the way that those
replicates are considered to yield the ﬁnal result. Typically, both
BCR-ABL1 and the reference gene are tested in duplicate, although
some centers perform triplicate assays and some only perform
single assays. If replicate assays are performed for BCR-ABL1 (as
recommended from RNA19,20 or cDNA21 to help improve
the accuracy of results) and any of the individual replicates
are positive according to the criteria above, we recommend that
the ﬁnal result is considered as positive, that is, detectable disease.
Even when testing in triplicate and two replicates are scored as
undetectable and one is scored as detectable, the overall result
should be scored as detectable or positive.
The Europe Against Cancer deﬁnes assay sensitivity by using
normalized copy number and ΔΔCt methods, both of which relate
the level of MRD to pretreatment levels for individual patients.22
This is not compatible with the IS in CML, which relates MRD levels
to the IRIS standardized baseline, and therefore an alternative
approach is required.
SCORING MR WHEN DISEASE IS DETECTABLE
In general, measurable residual disease23 should be assigned a
value on the IS and scored as MR4 if ⩽ 0.01% BCR-ABLIS, MR4.5 if
⩽ 0.0032% BCR-ABLIS, and so on, provided that the sample fulﬁls
the minimum quality criteria, that is, ABL1 ⩾ 10 000 or GUSB
⩾ 24 000 in each replicate.21 If replicate analyses are performed
and the values between replicates are comparable,21 then the
number of BCR-ABL1 and reference gene transcripts should be
the total value across replicates and the ﬁnal result expressed on
the IS, that is, ((sum of BCR-ABL1 copies)/(sum of reference gene
copies)) × CF × 100 (see examples 1–3). As the reference gene in
this context is used to estimate the amount of cDNA tested for
BCR-ABL1, any difference in the number of replicates performed
for BCR-ABL1 and the reference gene will need to be taken into
account (see example 4). In addition, we recommend that for
scoring MR4.5, the total reference gene number should be 32 000–
99 999 ABL1 transcripts or 77 000–239 999 GUSB transcripts
regardless of whether the disease is detectable or undetectable.
For scoring MR5, the total reference gene number should be ABL1
⩾ 100 000 or GUSB ⩾ 240 000 (Table 1; see example 5).
Many centres score positive samples with a Cq higher than that
of the lowest plasmid standard as ‘low-level positive’, positive
outside the quantiﬁable range, ‘o10 BCR-ABL1’, if the lowest
standard is 10, ‘o4 BCR-ABL1’, if the lowest standard is 4, and so
on. Indeed, some guidelines speciﬁcally recommend that values
should not be estimated if they require extrapolation beyond the
Table 1. Summary of reference gene numbers required for scoring deep molecular response
MR4 MR4.5 MR5
Minimum sum of reference gene transcripts irrespective of
whether BCR-ABL1 is detected or nota
10 000 ABL1
24 000 GUSB
32 000 ABL1
77 000 GUSB
100 000 ABL1
240 000 GUSB
BCR-ABLIS level for positive samplesb ⩽ 0.01% ⩽ 0.0032% ⩽ 0.001%
aNumbers of reference gene transcripts in same volume of cDNA that is tested for BCR-ABL1. The minimum number in any individual replicate should be
10 000 ABL1 or 24 000 GUSB. bProvided that the minimum reference gene copy numbers in the row above are fulﬁlled.
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span of the standard plasmid calibration curve.21 This presents a
problem for scoring low levels of disease and means, for example,
that a laboratory using 10 as the lowest standard and a CF= 1
would need to achieve ABL1 reference gene values of 100 000 or
greater to be able to score a sample with low-level detectable
disease as MR4 and a value of ⩽ 320 000 to score a similar sample
as MR4.5 (o10 BCR-ABL1/320 000 ABL1=⩽ 0.0032% BCR-ABL1).
Despite the signiﬁcant errors in quantifying small numbers of
target molecules, we suggest that all low level-positive replicates
should be assigned a speciﬁc number of BCR-ABL1 transcripts by
extrapolating below the lowest plasmid standard.
Testing laboratories have generally not rigorously determined
their in-house limit of detection (LoD; deﬁned as the lowest
concentration of target that can be detected with 95%
conﬁdence) for BCR-ABL1 transcripts. One reason for this is that
standardized reagents have not been available to perform LoD
analysis in a reproducible manner. Now, with the availability of
the ERM-AD623 plasmid17 and other calibration reagents,8 we
recommend that laboratories speciﬁcally measure24 and optimize
their BCR-ABL1 LoD. Clearly, the accuracy and precision by which
MR can be scored critically depends on the BCR-ABL1 LoD being
maximized. A laboratory with a poor LoD may score a sample as
undetectable and deep MR, whereas a laboratory with an
optimized LoD may detect BCR-ABL1 in the same sample and
score it as not deep MR. Several studies have indicated that qPCR
can be routinely optimized to detect single target molecules.25–27
Assuming that a single BCR-ABL1 cDNA target can be detected
and that there is no background signal (limit of blank = 0), the LoD
given by the Poisson distribution as three BCR-ABL1 targets, as for
a sample with an average of 3 targets/unit volume, there is a 95%
chance that any unit volume will contain at least one target
(Figure 1). Thus, we recommend that any replicate scored as
positive should be assigned a value of ⩾ 3 BCR-ABL1 copies, that is,
positive replicates with estimated copy numbers of o3 should
be scored as 3 (see examples 6–8). Alternative technologies, for
example, digital PCR, are likely to be more accurate than qPCR for
estimating small numbers of target molecules and may well
become the method of choice for more accurate deﬁnition of
low-level positive disease.28,29
SCORING MR WHEN DISEASE IS UNDETECTABLE
Analysis of multiple replicates can increase the sensitivity of
detection simply by increasing the amount of sample that is
tested. This approach has been used to design very sensitive
assays to detect BCR-ABL1 by qRT-PCR in healthy individuals,30 for
genomic DNA-based tests for BCR-ABL1 in CML,31–33 for detection
of minimal residual disease in lymphoid disorders25 and for other
applications such as noninvasive prenatal testing.34 When BCR-
ABL1 is undetectable in all replicates from the same sample, we
recommend that the ﬁnal result is given as (undetectable BCR-
ABL1)/(sum of reference gene in all the replicates). We suggest
that for routine analysis, a maximum of two or three replicates are
performed (examples 9–11), although for speciﬁc studies it may be
desirable to perform more replicates. Stringent quality criteria are
essential, speciﬁcally replicates with o10 000 ABL1 or o24 000
GUSB transcripts should be considered as inevaluable for
determining deep MR (examples 12 and 13), and laboratories
should maximize their LoD for BCR-ABL1 to avoid false-negative
results. As above, any difference in the number of replicates
performed for BCR-ABL1 and the reference gene should be taken
into account (example 14).
EXAMPLES
BCR-ABL1 detected in at least one replicate
● Example 1 (Lab CF = 0.8):
– BCR-ABL1 replicate 1: detectable in 2 μl cDNA, estimated 7
copies.
– BCR-ABL1 replicate 2: detectable in 2 μl cDNA, estimated 3
copies.
– ABL1 replicate 1: 24 000 copies in 2 μl cDNA.
– ABL1 replicate 2: 28 000 copies in 2 μl cDNA.
Result = (sum BCR-ABL1= 10)/(sum ABL1= 52 000) × 0.8 × 100=
0.015%=MMR but not MR4.
● Example 2 (Lab CF = 1.8):
– BCR-ABL1 replicate 1: undetectable in 5 μl cDNA.
– BCR-ABL1 replicate 2: detectable in 5 μl cDNA, estimated 3
copies.
– GUSB replicate 1: 43 000 copies in 5 μl cDNA.
– GUSB replicate 2: 49 000 copies in 5 μl cDNA.
Result = (sum BCR-ABL1= 3)/(sum GUSB= 92 000) × 1.8 × 100 =
0.0059%=MR4.
Comment: Testing laboratories use different amounts of RNA to
make cDNA, make different volumes of cDNA and use different
volumes of cDNA for individual qPCR assays. The number of
reference gene transcripts should be estimated in the same volume
of cDNA used to test for BCR-ABL1. The use of other reference genes,
for example, BCR, is possible, but the number of transcripts required
to deﬁne different levels of MR remain to be determined.
● Example 3 (Lab CF = 0.5):
– BCR-ABL1 replicate 1: undetectable in 5 μl cDNA.
– BCR-ABL1 replicate 2: detectable in 5 μl cDNA, estimated 3
copies.
– ABL1 replicate 1: 9000 copies in 5 μl cDNA.
– ABL1 replicate 2: 8000 copies in 5 μl cDNA.
Result = inevaluable for MR.
Comment: Although the ((sum of BCR-ABL1)/(sum of reference
gene)) × CF × 100 is o0.01%, the sample should be considered as
inevaluable for the assessment of MR as the ABL1 copy number in
each replicate is o10 000.
● Example 4 (Lab CF = 0.8):
– BCR-ABL1 replicate 1: undetectable in 5 μl cDNA.
– BCR-ABL1 replicate 2: undetectable in 5 μl cDNA.
– BCR-ABL1 replicate 3: detectable in 5 μl cDNA, estimated 4
copies.
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Figure 1. LoD of BCR-ABL1 detection. The graph shows the Poisson
distribution with a mean of 3 BCR-ABL1 targets per well. The
percentage of wells with 0–10 targets per well is indicated (20 000
computer-generated random datapoints; Minitab version 16,
Coventry, UK) and shows that 95% of wells has at least one
BCR-ABL1 target. As the LoD is deﬁned as the lowest concentration
of target that can be detected with 95% conﬁdence, the maximal
theoretical LOD is 3 copies.
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– ABL1 replicate 1: 14 000 copies in 5 μl cDNA.
– ABL1 replicate 2: 15 000 copies in 5 μl cDNA.
Result = (sum BCR-ABL1= 4)/(sum ABL1= 29 000 × 1.5) × 0.8 ×
100= 0.0074%=MR4.
Comment: The sum of the reference gene copy number is
multiplied by 1.5 (equivalent to multiplying the mean copy
number × 3) because only two replicates were performed for
the reference gene, whereas three replicates were performed for
BCR-ABL1. In general, we consider that it is better to perform the
same number of replicates for BCR-ABL1 and the reference gene.
● Example 5 (Lab CF= 0.25):
– BCR-ABL1 replicate 1: undetectable in 2 μl cDNA.
– BCR-ABL1 replicate 2: detectable in 2 μl cDNA, estimated 3
copies.
– ABL1 replicate 1: 12 000 copies in 2 μl cDNA.
– ABL1 replicate 2: 14 000 copies in 2 μl cDNA.
Result = (sum BCR-ABL1= 3)/(sum ABL1= 26 000) × 0.25 × 100
= 0.0029%; sum of ABL1 o32 000 =MR4.
Comment: Although the ((sum of BCR-ABL1)/(sum of reference
gene)) ×CF×100 is o0.0032%, the total ABL1 value is o32 000 and
should thus be considered as MR4. Considering the extreme
examples of 31 999 ABL1 transcripts and either 0 or 3 BCR-ABL1
transcripts, it is apparent that this discrepancy only arises if the CF is
o0.35 if using ABL1 as a reference gene (or o0.82 if using GUSB).
● Example 6 (Lab CF= 0.8):
– BCR-ABL1 replicate 1: undetectable in 5 μl cDNA.
– BCR-ABL1 replicate 2: detectable in 5 μl cDNA, estimated
2 copies.
– ABL1 replicate 1: 18 000 copies in 5 μl cDNA.
– ABL1 replicate 2: 16 500 copies in 5 μl cDNA.
Result = (sum BCR-ABL1= 3)/(sum ABL1= 34 500) × 0.8 × 100 =
0.007%=MR4.
Comment: Each positive replicate should be assigned a value
of ⩾ 3 copies and therefore the second BCR-ABL1 replicate is
scored as 3 copies.
● Example 7 (Lab CF= 0.8):
– BCR-ABL1 replicate 1: detectable in 5 μl cDNA, estimated
2 copies.
– BCR-ABL1 replicate 2: detectable in 5 μl cDNA, estimated
1 copy.
– ABL1 replicate 1: 18 000 copies in 5 μl cDNA.
– ABL1 replicate 2: 16 500 copies in 5 μl cDNA.
Result = (sum BCR-ABL1= 6)/(sum ABL1= 34 500) × 0.8 × 100 =
0.014%=MMR but not MR4.
Comment: Each positive replicate should be assigned a value of ⩾3
copies and therefore each BCR-ABL1 replicate is scored as 3 copies.
● Example 8 (Lab CF= 0.8):
– BCR-ABL1 replicate 1: detectable in 5 μl cDNA, estimated
2 copies.
– BCR-ABL1 replicate 2: detectable in 5 μl cDNA, estimated
5 copies.
– BCR-ABL1 replicate 3: detectable in 5 μl cDNA, estimated
7 copies.
– ABL1 replicate 1: 34 000 copies in 5 μl cDNA.
– ABL1 replicate 2: 38 500 copies in 5 μl cDNA.
– ABL1 replicate 3: 32 500 copies in 5 μl cDNA.
Result = (sum BCR-ABL1= 15)/(sum ABL1= 105 000) × 0.8 × 100=
0.011%=MMR but not MR4.
Comment: Each positive replicate should be assigned a value of
⩾ 3 copies.
BCR-ABL1 undetected in all replicates
● Example 9:
– BCR-ABL1 replicate 1: undetectable in 5 μl cDNA.
– BCR-ABL1 replicate 2: undetectable in 5 μl cDNA.
– ABL1 replicate 1: 16 500 copies in 5 μl cDNA.
– ABL1 replicate 2: 18 000 copies in 5 μl cDNA.
Result = undetectable BCR-ABL1 in 34 500 ABL1=MR4.5.
● Example 10:
– BCR-ABL1 single analysis: undetectable in 5 μl cDNA.
– ABL1 single analysis: 45 000 copies in 5 μl cDNA.
Result = undetectable BCR-ABL1 in 45 000 ABL1=MR4.5.
Comment: Although single analyses are performed by some
centers, replicate assays from RNA or cDNA improves the accuracy
of results.19–21
● Example 11:
– BCR-ABL1 replicate 1: undetectable in 2 μl cDNA.
– BCR-ABL1 replicate 2: undetectable in 2 μl cDNA.
– BCR-ABL1 replicate 3: undetectable in 2 μl cDNA.
– ABL1 replicate 1: 24 000 copies in 2 μl cDNA.
– ABL1 replicate 2: 22 500 copies in 2 μl cDNA.
– ABL1 replicate 3: 24 000 copies in 2 μl cDNA.
Result = undetectable BCR-ABL1 in 70 500 ABL1=MR4.5.
● Example 12:
– BCR-ABL1 replicate 1: undetectable in 5 μl .
– BCR-ABL1 replicate 2: undetectable in 5 μl cDNA.
– ABL1 replicate 1: 7000 copies in 5 μl cDNA.
– ABL1 replicate 2: 8000 copies in 5 μl cDNA.
Result = inevaluable for MR as ABL1 o10 000 in each replicate.
● Example 13:
– BCR-ABL1 replicate 1: undetectable in 5 μl cDNA.
– BCR-ABL1 replicate 2: undetectable in 5 μl cDNA.
– ABL1 replicate 1: 6000 copies in 5 μl cDNA.
– ABL1 replicate 2: 14 000 copies in 5 μl cDNA.
Result = inevaluable for MR.
Comment: One replicate is o10 000 ABL1 and hence the sample
should be considered as inevaluable for MR. As the two ABL1
replicates are discordant, the reference gene qPCR could be repeated.
● Example 14:
– BCR-ABL1 replicate 1: undetectable in 2 μl cDNA.
– BCR-ABL1 replicate 2: undetectable in 2 μl cDNA.
– BCR-ABL1 replicate 3: undetectable in 2 μl cDNA.
– ABL1 replicate 1: 16 500 copies in 2 μl cDNA.
– ABL1 replicate 2: 18 000 copies in 2 μl cDNA.
Result = undetectable BCR-ABL1 in (34 500 × 1.5 = 51 750
ABL1) =MR4.5.
Comment: The sum of the reference gene copy number is multiplied
by 1.5 because only two replicates were performed for the reference
gene, whereas three replicates were performed for BCR-ABL1.
CONCLUDING REMARKS
The remarkable progress in the treatment of CML has demanded
deﬁnitions of deep MR that are stretching the technology of
molecular monitoring to its limit. The recommendations described
here are an attempt to develop standardized laboratory
approaches that strike a reasonable balance between scientiﬁc
accuracy and clinical reality. It should be recognized that there is
considerable inherent uncertainty in deﬁning very low levels of
disease and that it will be important to continue to look at trends
over time to recognize sustained MR. Furthermore, the reprodu-
cible application of the recommendations depends critically on
the ability of testing laboratories to measure absolute numbers of
reference gene transcripts in a comparable manner, as well as
their ability to maximize the LoD for BCR-ABL1 and minimize
interassay variability. It is obvious that future methodological
improvements that increase the amount of sample tested
(as determined by the number of reference gene transcripts) will
increase the precision and accuracy of scoring MR4 or MR,4.5 as
well as enabling even deeper levels of MR to be determined.
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We recognize that these recommendations may need to be
adapted to local requirements and changing technologies.
We also recognize that laboratory recommendations in isolation
are meaningless and that the critical question is the clinical
signiﬁcance of achieving deep levels of MR. We anticipate that
the standardized deﬁnitions described here will help to progress
clinical studies that aim ultimately to cure CML as well as
providing a common framework for reporting routine results.
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